angiotensin at1 receptor

L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol.

Angiotensin II (3-8), human (TFA), is an angiotensin AT1 receptor agonist with reduced activity.

A81988 is an antagonist of angiotensin AT1 receptors.

SL910102 is a nonpeptide angiotensin antagonist of the AT1 receptor.

ME-3221 is an angiotensin AT1 receptor antagonist that prevents hypertensive complications in aged stroke-prone hypertensive rats.

Losartan potassium (DuP-753 potassium), an Angiotensin II Receptor Blocker, selectively and competitively inhibits the binding of angiotensin II to the angiotensin I (AT1) receptor.

Losartan (DuP-753) is an angiotensin II receptor antagonist.

Azilsartan (TAK-536) is an Angiotensin 2 Receptor Blocker that acts as an Angiotensin 2 Type 1 Receptor Antagonist, leading to a physiologic effect of decreased blood pressure.

Olmesartan Medoxomil (Benicar) is an angiotensin II type 1 receptor blocker that is used to manage hypertension.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist (IC50: 0.26 nM). Upon hydrolysis to candesartan during gastrointestinal absorption, it selectively competes with angiotensin II for binding to the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation.

Eprosartan Mesylate (SKF-108566J) is a competitive and reversible Angiotensin II Receptor Blocker.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

UR-7247 is a novel orally active angiotensin II subtype I (AT1) antagonist, demonstrating very long pharmacological effects. in vivo studies indicate no significant difference between 10 mg UR-7247 and 100 mg losartan four hours post-administration, while in vitro blockade with 100 mg losartan exceeds that observed with UR-7247, confirming UR-7247’s extended plasma half-life potentially due to high-affinity protein binding, highlighting its long-lasting, well-tolerated AT1 receptor antagonism in healthy subjects.

Angiotensin III is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Angiotensin III TFA is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Candesartan-D4 is the deuterated form of Candesartan (TMSM-3481). It is an orally active Angiotensin II AT1 receptor blocker and PPAR-γ agonist with long-lasting antihypertensive effects, used as an internal standard in PK studies.

Losartan-D4 is a deuterated isotope of Losartan (T0215L) for isotopic tracing. Losartan (T0215L) is an angiotensin II receptor antagonist (IC50=20 nM).

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

BMS-248360 is a potent, orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptors, respectively. BMS-248360 demonstrates hypertensive effects[1].